Clinical Trial Update: A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, and efficacy of ACE-011 in patients with osteolytic lesions due to multiple myeloma has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ACE-011

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2024-10-03